Is the future of healthcare really being decided at a VR conference in Los Angeles? That’s the question nagging at me as I read about the buzz surrounding Vive, a showcase for virtual and augmented reality technologies. Everyone’s talking about immersive experiences, digital twins, and the metaverse’s potential to revolutionize medicine. But the real story here isn’t the shiny new headsets – it’s the increasingly desperate search for a compelling use case that justifies the massive investment in these technologies, and whether that search is distracting us from more pressing, practical needs.
The Hype Cycle and Healthcare’s Wallet
Mario Aguilar of STAT News is right to point out the allure of escaping a New England winter for the California sun at events like Vive. But the sunshine is a distraction. We’ve been down this road before. Remember the initial fervor around telehealth, promising to democratize access to care? It delivered some benefits, particularly during the pandemic, but also exposed deep inequities in broadband access and digital literacy. The telehealth boom of 2020 saw a 38X increase in claims compared to 2019, according to the American Medical Association, but that growth has since stabilized, and reimbursement policies remain a chaotic patchwork. VR/AR faces a similar risk: becoming a solution in search of a problem, fueled by venture capital and breathless marketing, rather than genuine patient need.
Based on the original STAT report.
Beyond Gaming: Where VR/AR Could Matter
Let’s be clear: VR and AR aren’t inherently useless in healthcare. There’s legitimate potential in surgical training, allowing surgeons to practice complex procedures in a risk-free environment. Osso VR, for example, has raised over $100 million to develop realistic surgical simulations. Pain management is another promising area, with studies showing VR can distract patients from discomfort during wound care or chemotherapy. But these applications, while valuable, are niche. They address specific problems for specific patient populations. The grand visions of a “metaverse hospital” where doctors collaborate in virtual spaces and patients receive immersive therapy feel…distant. And expensive. The cost of entry – both for healthcare providers and patients – remains a significant barrier.
The Digital Divide and the Illusion of Progress
The focus on cutting-edge tech also risks exacerbating existing health disparities. While Silicon Valley dreams of digital twins and personalized medicine, millions of Americans still lack basic access to primary care. A 2023 report from the Kaiser Family Foundation found that over 27 million people in the US are uninsured. Investing heavily in technologies that require smartphones, high-speed internet, and a certain level of tech savviness effectively excludes a large segment of the population. It’s a classic case of innovation benefiting those who already have access, while leaving others further behind. This isn’t about rejecting progress; it’s about prioritizing equitable progress.
The Real Cost of “Future-Proofing”
The allure of “future-proofing” healthcare – building systems that are ready for whatever technological marvel comes next – is strong. But it’s also incredibly expensive. Every dollar spent on developing a VR-based therapy is a dollar not spent on addressing social determinants of health, improving preventative care, or reducing administrative burdens. We need to ask ourselves: are we solving the right problems? Are we focusing on technologies that will have the greatest impact on the largest number of people? Or are we simply chasing the next shiny object, hoping it will magically fix a broken system?
Here’s what I’m watching for: in the next 18 months, keep an eye on the reimbursement landscape for VR/AR therapies. If major insurers refuse to cover these treatments beyond limited pilot programs, it will be a clear signal that the hype has outstripped the reality. The question isn’t if VR/AR will have a place in healthcare, but how significant that place will be. And right now, I suspect it will be a relatively small one, overshadowed by the more fundamental challenges facing the industry.
